Rocket Pharmaceuticals, Inc.
NASDAQ:RCKT
16.98 (USD) • At close November 1, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 7.098 | 6.266 | 5.373 | 1.145 | 0.426 | 0.33 | 0.204 | 0.169 | 0.045 | 0 | 0 | 0 |
| Gross Profit
| -7.098 | -6.266 | -5.373 | -1.145 | -0.426 | -0.33 | -0.204 | -0.169 | -0.045 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 186.342 | 165.57 | 125.476 | 106.382 | 58.623 | 53.27 | 14.193 | 31.985 | 12.554 | 5.592 | 5.33 | 3.542 |
| General & Administrative Expenses
| 73.317 | 58.773 | 41.772 | 27.921 | 17.528 | 17.886 | 12.544 | 9.894 | 7.842 | 2.112 | 1.324 | 2.307 |
| Selling & Marketing Expenses
| -1.723 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 73.317 | 58.773 | 41.772 | 27.921 | 17.528 | 17.886 | 12.544 | 9.894 | 7.842 | 2.112 | 1.324 | 2.307 |
| Other Expenses
| 0 | -0.5 | -1 | 0 | -0.25 | 0.186 | 0 | 0 | 0 | 0 | 0.003 | 0.004 |
| Operating Expenses
| 249.008 | 223.843 | 166.248 | 134.303 | 75.901 | 70.97 | 26.737 | 41.879 | 20.396 | 7.704 | 6.654 | 5.849 |
| Operating Income
| -259.659 | -224.343 | -167.248 | -134.303 | -76.151 | -71.156 | -26.737 | -41.879 | -20.396 | -7.704 | -6.654 | -5.849 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 14.064 | 2.48 | -1.821 | -5.397 | -1.119 | 0.801 | -2.76 | -0.975 | -46.445 | -0.847 | -0.078 | 0.004 |
| Income Before Tax
| -245.595 | -221.863 | -169.069 | -139.7 | -77.27 | -74.518 | -29.497 | -42.854 | -67.982 | -9.531 | -7.616 | -6.058 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | -2.48 | 0.516 | 6.967 | 5.958 | 2.677 | 0.819 | 0.443 | 1.23 | 0 | 0.884 | 0.217 |
| Net Income
| -245.595 | -219.383 | -169.585 | -146.667 | -83.228 | -74.518 | -29.497 | -42.854 | -67.982 | -9.531 | -7.616 | -6.058 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -2.92 | -3.22 | -2.68 | -2.65 | -1.7 | -1.89 | -4.36 | -6.41 | -14.85 | -2.79 | -3.62 | -2.88 |
| EPS Diluted
| -2.92 | -3.22 | -2.68 | -2.65 | -1.7 | -1.89 | -4.36 | -6.41 | -14.85 | -2.79 | -3.62 | -2.88 |
| EBITDA
| -252.561 | -213.688 | -163.18 | -131.008 | -72.061 | -68.95 | -25.718 | -41.267 | -20.262 | -7.704 | -6.651 | -5.836 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |